Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China

Journal of International Medical Research

Volumn 37, Issue 3, 2009, Pages 812-821

  Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Blood glucose control; Double blind randomized non inferiority study; Mitiglinide; Nateglinide; Rapid acting insulin secretagogues; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; MITIGLINIDE; NATEGLINIDE; PLACEBO; ANTIDIABETIC AGENT; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; ISOINDOLE DERIVATIVE; PHENYLALANINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHINA; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIET; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ENTERITIS; EXERCISE; FEMALE; GASTRITIS; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEPATOSIS; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; HYPOGLYCEMIA; HYPOLEUKEMIA; INSULIN RELEASE; LEUKEMIA; LIVER DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOOTH PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COMPARATIVE STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; CHINA; CYCLOHEXANES; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISOINDOLES; MALE; MIDDLE AGED; PHENYLALANINE; TREATMENT OUTCOME;

EID: 70349260322     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700324     Document Type: Article

References (16)

1. International Diabetes Federation (IDF): Diabetes Atlas. Brussels: IDF (available at http://www.eatlas.idf.org/).
2. Balkau B, Shipley M, Jarrett RJ, et al: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367. (Pubitemid 28101069)
3. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
4. Tominaga M, Igarashi K, Eguchi H, et al: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924. (Pubitemid 29241045)
5. Rosenstock J, Hassman DR, Madder RD, et al: Repaglinide versus nateglinide monotherapy. Diabetes Care 2004; 27: 1265-1270.
6. Hu S, Wang S, Dunning BE: Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and β-cell KATP channels. J Pharmacol Exp Ther 1999; 291: 1372-1379.
7. Hatorp V, Hansen KT, Thomsen MS: Influence of drugs interacting with CYP3A4 on pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003; 43: 649-660. (Pubitemid 36613124)
8. Kajosaari LI, Laitila J, Neuvonen PJ, et al: Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005; 97: 249-256. (Pubitemid 41433700)
9. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, et al: CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56: 305-314. (Pubitemid 37059658)
10. Diabetes Control and Complication Trial (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. (Pubitemid 23307905)
11. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
13. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. (Pubitemid 28416719)
14. Novartis Pharmaceuticals Corporation: Starlix® (nateglinide) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2004.
15. Raz I, Hanefeld M, Xu L, et al for the Sitagliptin Study 023 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
16. Aschner P, Kipnes MS, Lunceford JK, et al: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637. (Pubitemid 44912190)